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ABSTRACT: Primary tumors of the trachea are rare and are usually
malignant in adults and benign in children. Adenoid cystic carci-
noma, which is of salivary gland origin, account for about one thirds
of adult primary tracheal tumors. A 49-year-old gentleman presented
to us after undergoing a pneumonectomy elsewhere. Computed
tomography scan of the thorax at our hospital showed a residual
disease in the primary site, size of which was same as that in the
preoperative scan. Because there was a compromised respiratory
reserve due to pneumonectomy we decided to keep the radiation
dose to the remaining lung as low as possible. We treated him by
positron emission tomography-computed tomography (PET-CT) di-
rected intensity modulated radiation therapy to a dose of 60 Gy in 30
Fractions over 6 weeks on a linear accelerator. PET helped in exact
localization of the target on the planning CT. He tolerated the
treatment very well. PET-CT done 1 year posttreatment showed no
residual disease. Presently he is disease free with good pulmonary
reserve.
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Primary tracheal tumors account for 0.1 to 0.4% of malig-nant diseases, with 2.6 new cases arising per million
people every year.1 Only 8% of these tumors develop in
children.2 Primary tracheal tumors can arise from the respi-
ratory epithelium, salivary glands, and mesenchymal struc-
tures of the trachea.1In adults, 90% of primary tumors are
malignant, compared with 10 to 30% in children.2 Squamous-
cell carcinoma and adenoid cystic carcinoma, which occur in
about the same proportions, account for about two thirds of
adult primary tracheal tumors. The remaining third are dis-
tributed widely in a heterogeneous group of malignant or
benign tumors. Here we report a case of adenoid cystic
carcinoma of the trachea treated by postoperative positron
emission tomography-computed tomography (PET-CT) di-
rected Intensity modulated radiation therapy (IMRT).
CASE SUMMARY
A 49-year-old gentle man presented in February 2006
with history of wheezing of 1 month duration. He also had
one episode of hemoptysis. General physical examination
was normal. Auscultation of the chest showed a decreased air
entry on the left side of thorax with rhonchi. Examination of
other systems did not reveal any significant abnormality. CT
scan of the chest was done which showed a 4  3  2-cm
mass in the posterior wall of carina toward the left side. There
were no pulmonary parenchymal lesions. There was no evi-
dence of mediastinal or hilar lymphadenopathy. Bronchos-
copy confirmed the friable mass on the posterior wall of the
carina going toward the left main bronchus. Biopsy from the
mass showed features of adenoid cystic carcinoma. Meta-
static work up including Ultrasound of the abdomen and bone
scan was normal. A complete blood hemogram and biochem-
istry did not reveal any abnormality. He then underwent left
pneumonectomy elsewhere. He was referred to us in April
2006 for further treatment. A repeat CT scan of the thorax at
our hospital showed a residual disease in the primary site,
size of which was same as that in the preoperative scan
(Figures 1, 2). There was evidence of left pneumonectomy
with shift of mediastinum to the left. He was then reevaluated
by our thoracic surgeons who opined that resurgery will be
difficult because the tumor was very close to the great
vessels. We decided to treat him by radiotherapy. Because
there was an already compromised respiratory reserve due to
pneumonectomy, we decided to keep the radiation dose to the
remaining lung as low as possible. We treated him by
PET-CT based IMRT with five fields to a dose of 60 Gy in 30
fractions over 6 weeks on a linear accelerator. PET helped in
exact localization of the target on the planning CT (Figure 3).
Figure 4 shows the field arrangement used and Figure 5 shows
the excellent dose distribution with the 95% color wash
perfectly covering the planning target volume. The confor-
mality index was 1.2. Patient tolerated the treatment very well
without any significant toxicity. PET-CT done at 1 year
postradiotherapy showed no residual disease. Presently he
has completed 19 months of follow-up and is disease free
with good pulmonary reserve.
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DISCUSSION
Adenoid cystic carcinoma of the trachea is equally
distributed between the sexes and is most common in patients
in their fourth and fifth decades of life. They are not associ-
ated with cigarette smoking, have a propensity to spread
along both submucosal and perineural planes, and only 10%
of patients have regional lymph-node metastases or distant
metastases. Moreover, adenoid cystic carcinoma progresses
slowly, often over several years.
Adenoid cystic carcinomas commonly present with
wheezing or stridor as the main symptom, and fewer than
25% of patients have hemoptysis early in their course, which
explains why there is a delay in the diagnosis and most
patients with primary malignant tracheal tumors still present
with advanced disease.3,4
CT is the most useful method to assess tracheal tumors
radiologically, and is regarded as the standard imaging tech-
nique for diagnosis and to assess the extent of the tumor and
the delineation of the relation of the tumor with adjacent
structures. Multiplanar and three-dimensional reconstruction
(virtual bronchoscopy) is an excellent modality. magnetic
resonance imaging provides advantage over CT in the assess-
ment of adenoid cystic carcinoma of trachea.
Surgery is the standard treatment of tracheal tumors if
possible. The need for oncological radicality needs to be
balanced against anastomotic tension, and some acceptance
of tumor bearing margins is needed in adenoid cystic carci-
nomas because postoperative radiotherapy can treat these
efficiently.
Adenoid cystic carcinoma is a relatively radiosensitive
disease. Radiotherapy has got a definite role in the manage-
ment of these cases. Matsuba et al.5 reported 76 patients of
salivary gland adenoid cystic carcinomas treated with surgery
and/or RT between 1963 and 1980; 24 (32%) of 76 patients
were treated for recurrence after prior therapy. The 10-year
local control rate was 83% after surgery and RT compared
with 25% after surgery alone. Miglianico et al.6 reported 102
patients of cervico-facial adenoid cystic carcinoma treated at
the Institut Gustave Roussy between 1951 and 1980 with
surgery (38 patients), RT (21 patients), or surgery and RT (43
patients). The 5-year locoregional control rates were 44%
after surgery compared with 78% after surgery and RT (p 
0.01).
FIGURE 1. Computed tomography scan of the thorax (ax-
ial section) showing a mass (pointed by arrow) in the region
of carina.
FIGURE 2. Computed tomography scan of the thorax
(coronal section) showing the tracheal mass (pointed by ar-
row) in close proximity to the great vessels.
FIGURE 3. Positron emission tomography
(PET) image showing intense fluoro-deoxy glu-
cose (FDG) uptake in the region of the tumor
which helps to contour the gross tumor vol-
ume (GTV).
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Radiotherapy is indicated as an adjuvant after resection,
for tumors that are unresectable or medically inoperable, and
for palliation of severe symptoms.7–9 The usual dose of
postoperative radiotherapy is 60 Gy given as 2 Gy per
fraction, five fractions per week, over 6 weeks. This treatment
kills residual microscopic carcinoma in the tumor bed and
regional lymph nodes. Endotracheal brachytherapy is an
excellent method to boost the primary or to palliate cases.
Debridement procedures like electro-coagulation, cryother-
apy, laser, photodynamic therapy, and stents does not have a
radical intent.
The main use of fluoro-deoxy glucose (FDG)-PET in
the radiotherapy planning process is in the delineation of the
primary tumor gross tumor volume. For the primary tumor,
the benefit of FDG-PET in the radiotherapy planning process
should be evaluated more in terms of three-dimensional
delineation and demarcation of the tumor volume from peri-
tumoral inflammation, edema, or atelectasis. When PET is
used in the radiotherapy planning process a strict methodol-
ogy has to be followed, including the use of a flat table top
with similar immobilization of the patient as on the treatment
couch, the systematic use of a transmission scan to correct for
body attenuation, the registration with thin CT slices, and the
use of automatic segmentation of the FDG-PET positive
spots. In addition, for thoracic lesions, the use of gated PET
acquisition might be required to avoid the blurring effect
because of target motion.10
IMRT helps to modulate the fluence within the beam
leading to better dose within the target volume and minimiz-
ing the dose to surrounding critical structures. PET-CT di-
rected IMRT is an ideal way to deliver radiation in difficult
situations with compromised respiratory reserve.
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FIGURE 4. Five field intensity modulated radiation therapy
(IMRT) beam arrangement.
FIGURE 5. The dose distribution around the planning tar-
get volume (PTV) with 95% dose color wash perfectly en-
compassing the PTV.
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